Iterum Therapeutics plc Annual Net Income (Loss) Attributable to Parent in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Iterum Therapeutics plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2016 to 2023.
  • Iterum Therapeutics plc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$6.09M, a 57.2% decline year-over-year.
  • Iterum Therapeutics plc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$30.6M, a 1.75% increase year-over-year.
  • Iterum Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2023 was -$38.4M, a 13.6% increase from 2022.
  • Iterum Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2022 was -$44.4M, a 51.5% increase from 2021.
  • Iterum Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2021 was -$91.6M, a 76.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$38.4M +$6.06M +13.6% Jan 1, 2023 Dec 31, 2023 10-Q 2024-11-14
2022 -$44.4M +$47.1M +51.5% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 -$91.6M -$39.6M -76.1% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-28
2020 -$52M +$51.1M +49.6% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-16
2019 -$103M -$26.1M -33.8% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-28
2018 -$77.1M -$47.7M -162% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-12
2017 -$29.4M -$15.9M -118% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 -$13.5M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.